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Introduction {#cam41233-sec-0001}
============

Nasopharyngeal carcinoma (NPC) is a malignancy of the nasopharyngeal epithelium. Although NPC is rare globally, it is highly prevalent in southern China where the incidence is 20 to 50 cases per 100,000 males [1](#cam41233-bib-0001){ref-type="ref"}. Radiotherapy (RT) is the primary therapy for nonmetastatic NPC [2](#cam41233-bib-0002){ref-type="ref"}, [3](#cam41233-bib-0003){ref-type="ref"}. The tumor‐node‐metastasis (TNM) staging system for NPC is the most powerful tool for guiding the selection of treatment strategies and predicting the prognosis of patients with NPC [4](#cam41233-bib-0004){ref-type="ref"}. Although application of superior RT technique intensity‐modulated radiation therapy (IMRT) and addition of chemotherapy and the precise imaging technology magnetic resonance imaging (MRI) have improved locoregional control, the survival outcomes among patients with advanced NPC remain unsatisfactory [5](#cam41233-bib-0005){ref-type="ref"}, [6](#cam41233-bib-0006){ref-type="ref"}, [7](#cam41233-bib-0007){ref-type="ref"}. Therefore, the identification of clinically relevant prognostic factors to recognize patients at high‐risk of failure is necessary.

Radioresistance and chemoresistance are the main factors leading to distant metastasis and tumor progression [8](#cam41233-bib-0008){ref-type="ref"}. Tumor hypoxia is key factor in development of radio‐ and chemo‐resistance [9](#cam41233-bib-0009){ref-type="ref"}, [10](#cam41233-bib-0010){ref-type="ref"}. Numerous efforts have been made to identify tumor hypoxia‐related prognostic factors for NPC in recent years [11](#cam41233-bib-0011){ref-type="ref"}, [12](#cam41233-bib-0012){ref-type="ref"}, [13](#cam41233-bib-0013){ref-type="ref"}, [14](#cam41233-bib-0014){ref-type="ref"}, [15](#cam41233-bib-0015){ref-type="ref"}, [16](#cam41233-bib-0016){ref-type="ref"}, [17](#cam41233-bib-0017){ref-type="ref"}, [18](#cam41233-bib-0018){ref-type="ref"}, [19](#cam41233-bib-0019){ref-type="ref"}, [20](#cam41233-bib-0020){ref-type="ref"}; hemoglobin (Hb) levels and cervical node necrosis (CNN) have attracted significant attention. Hb is the principal carrier of oxygen in red blood cells, which carry oxygen from the respiratory organs to the rest of the body. A low Hb level causes a reduction in blood oxygen and can lead to tumor hypoxia. CNN may indicate intratumoral hypoxia [21](#cam41233-bib-0021){ref-type="ref"}. Anemia or/and CNN may in turn affect the efficacy of RT and chemotherapy. Accumulating data suggests there are positive relationships between pretreatment hemoglobin (Hb) levels and CNN and the survival of patients with NPC treated with IMRT ± chemotherapy [11](#cam41233-bib-0011){ref-type="ref"}, [12](#cam41233-bib-0012){ref-type="ref"}, [13](#cam41233-bib-0013){ref-type="ref"}, [14](#cam41233-bib-0014){ref-type="ref"}, [15](#cam41233-bib-0015){ref-type="ref"}, [16](#cam41233-bib-0016){ref-type="ref"}, [17](#cam41233-bib-0017){ref-type="ref"}. As both anemia and CNN may serve as markers of low tumor oxygenation status, it is reasonable to hypothesize the pretreatment hemoglobin level may correlate with and complement CNN to enable improved prediction of the survival of patients with NPC. However, this relationship has not been confirmed experimentally.

We performed this retrospective study to evaluate the impacts of pretreatment anemia and CNN on survival outcomes and then investigated the combined prognostic value of these factors, with the aim of improving outcome prediction and enabling the elucidation of individualized strategies for treatment of patients with NPC undergoing IMRT.

Materials and Methods {#cam41233-sec-0002}
=====================

Patient selection and staging evaluation {#cam41233-sec-0003}
----------------------------------------

The inclusion criteria were: (1) had newly diagnosed, pathologically proven, previously untreated NPC; (2) with cervical node metastasis; (3) no evidence of distant metastases; (4) treated using IMRT ± chemotherapy at our cancer center from November 2009 to February 2012; (5) no other tumors or serious illnesses; (6) available pretreatment MRI scans of the nasopharynx and neck; (7) pretreatment Hb level available (measured ≤1 week before treatment); (8) and no other tumors or serious illnesses. The selection criteria were met by 1302 consecutive patients. Participants completed pretreatment baseline evaluations including a complete history, hematological and biochemical profiles, physical and neurological examination, chest radiography, MRI of the neck and nasopharynx, abdominal ultrasonography, and a whole‐body bone scan using single photon emission computed tomography. All participants were restaged based on the seventh edition of the International Union against Cancer/American Joint Committee on Cancer system [22](#cam41233-bib-0022){ref-type="ref"}. Patient records/information were collected by trained data reviewers and were analyzed anonymously. As this study was a retrospective assessment of routine data, the ethics committee of our Cancer Center waived the need for individual informed consent.

Treatment strategies {#cam41233-sec-0004}
--------------------

Treatment strategies were designed using standard protocols depending on clinical TNM stage and the general patient condition. In the relevant study period, institutional guidelines recommended concurrent chemoradiotherapy ± neoadjuvant/adjuvant chemotherapy for stage II to IVB as described previously [23](#cam41233-bib-0023){ref-type="ref"}. Every patient was treated with IMRT at one fraction/day, 5 days per week. IMRT was performed as described previously [23](#cam41233-bib-0023){ref-type="ref"}.

Concurrent chemotherapy consisted of cisplatin weekly or every 3 weeks during RT. Neoadjuvant/adjuvant chemotherapy was 1--4 cycles of cisplatin with docetaxel, cisplatin with 5‐fluorouracil or cisplatin with 5‐fluorouracil and docetaxel every 2 to 3 weeks.

Assessment of anemia and CNN {#cam41233-sec-0005}
----------------------------

Anemia was defined based on the Chinese Society of Clinical Oncology (CSCO) clinical practice guidelines and National Cancer Institute criteria on cancer‐related anemia: pretreatment hemoglobin \<120 g/L in males and \<110 g/L in females [21](#cam41233-bib-0021){ref-type="ref"}, [24](#cam41233-bib-0024){ref-type="ref"}, [25](#cam41233-bib-0025){ref-type="ref"}.

All patients underwent MRI using a 1.5‐T MR system (Signa CV/i; General Electric Healthcare, Chalfont St. Giles, United Kingdom) using a head and neck combined coil to examine the region from the suprasellar cistern to the inferior margin at the sternal end of the clavicle. Two radiologists specializing in HN cancer reviewed all MRI scans separately and any disagreements were resolved by discussion every 2 weeks. The definition of necrosis on MRI was T1‐weighted contrast‐enhanced images showing focal low‐signal intensity with or without a surrounding rim of enhancement or T2‐weighted images showing focal high‐signal intensity.

Patients were classified into four groups: non‐anemia and non‐CNN group, anemia group (anemia and non‐CNN group), CNN group (non‐anemia and CNN group), and anemia and CNN group.

Follow‐up and end‐points {#cam41233-sec-0006}
------------------------

Follow‐up time was measured from day 1 of treatment to the time of last visit or death. To detect possible locoregional relapse or distant metastasis, all patients underwent conventional examinations (similar to the pretreatment assessment) every 3 to 6 months during the first 24 months, and 6‐monthly thereafter until death. End‐points (from first day of treatment to first defining event) were overall survival (OS), disease‐free survival (DFS), distant metastasis‐free survival (DMFS), and locoregional relapse‐free survival (LRRFS).

Statistical analysis {#cam41233-sec-0007}
--------------------

Data analysis used Statistical Package for the Social Sciences version 17.0 software (SPSS, Chicago, IL, USA); Survival rates were calculated using the Kaplan--Meier method, and survival curves were compared using log‐rank tests. Clinical characteristics and failure patterns between groups were compared using the Chi‐square test or Fisher\'s exact test. If more than 20% of the expected count in cells is less than 5, use the Fisher\'s exact probability tests, otherwise use the Pearson chi‐square test. Univariate analysis was conducted using the log‐rank test. Multivariate analysis used the Cox proportional hazards model including the following covariates: gender, age, T category, N category, WHO histological type, presence or absence of pretreatment anemia, presence or absence of CNN, and chemotherapy (yes/no). Two‐tailed *P*‐values \< 0.05 were considered significant.

Results {#cam41233-sec-0008}
=======

Patient characteristics {#cam41233-sec-0009}
-----------------------

At diagnosis, the median age was 45 years (range, 14--78 years). A total of 178 patients (13.7%) were lost to follow‐up by the final follow‐up. Of the 1302 patients, 330 (25.3%) were female and 972 (74.7%) were male; 68 (5.2%) patients had type I or II disease and 1234 (94.8%) had type III disease; 291 (22.4%), 681 (52.3%), and 330 (25.3%) had stage II, III, IV NPC, respectively; and 1193/1302 (91.6%) patients received chemotherapy.

Mean pretreatment Hb value was 142 g/L (range, 82--177 g/L) and 6.8% (89/1302) and 34.4% (448/1302) of patients had pretreatment anemia and CNN, respectively. Of the 1302 patients, 801 (61.5%) did not have pretreatment anemia or CNN; 53 (4.1%) had pretreatment anemia but not CNN; 412 (31.6%) had CNN but not pretreatment anemia; and 36 (2.8%) had pretreatment anemia and CNN.

There was no significant difference in the distribution of age (*P *=* *0.459), histological type (*P *=* *0.627), chemotherapy strategies (*P *=* *0.461) or T category (*P *=* *0.197) when the patients were stratified by anemia; however, significant differences were observed in terms of sex (*P *=* *0.004) and N category (*P *=* *0.026). There was no significant difference in terms of age (*P *=* *0.826), sex (*P *=* *0.498) and histological type (*P *=* *0.867) when the patients were stratified by CNN. However, significant differences were observed in terms of T category (*P *=* *0.048), N category (*P *\<* *0.001), and chemotherapy strategies (*P *=* *0.001). The pretreatment clinicopathological characteristics of the 1302 patients are listed in Table [1](#cam41233-tbl-0001){ref-type="table-wrap"}.

###### 

Patient characteristics and treatment factors (*n *=* *1302)

                                                         Non‐anemia   Anemia   *P*     Non‐CNN   CNN   *P*
  ------------------------------------------------------ ------------ -------- ------- --------- ----- ---------
  Characteristic                                                                                       
  Age (years)                                                                  0.407                   0.512
  ≤45                                                    614          41               424       231   
  ˃45                                                    599          48               430       217   
  Gender                                                                       0.001                   0.257
  Male                                                   919          53               646       326   
  Female                                                 294          36               208       122   
  WHO pathology classification                                                 0.492                   0.968
  Type I                                                 7            1                5         3     
  Type II                                                54           6                40        20    
  Type III                                               1152         82               809       425   
  T category[a](#cam41233-note-0004){ref-type="fn"}                            0.062                   \<0.001
  T1                                                     200          10               152       58    
  T2                                                     193          7                130       70    
  T3                                                     625          53               464       214   
  T4                                                     195          19               108       106   
  N category[a](#cam41233-note-0004){ref-type="fn"}                            0.019                   \<0.001
  N1                                                     851          49               632       268   
  N2                                                     237          24               148       113   
  N3                                                     125          16               74        67    
  Overall stage[a](#cam41233-note-0004){ref-type="fn"}                         0.001                   \<0.001
  II                                                     282          9                212       79    
  III                                                    636          45               472       209   
  IV                                                     295          35               170       160   
  Chemotherapy                                                                 0.331                   0.001
  No                                                     104          5                88        21    
  Yes                                                    1109         84               766       427   

CNN, cervical node necrosis; WHO, World Health Organization.

According to the seventh edition of the American Joint Committee on Cancer.
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Treatment outcomes for the entire cohort {#cam41233-sec-0010}
----------------------------------------

The median follow‐up duration was 47.8 months (range, 1.3--75.3 months) for the entire cohort and 50.40 (range, 1.3--75.3 months) for the surviving patients. For the entire cohort, the 5‐year OS, DFS, DMFS, and LRRFS rates were 86.0%, 77.5%, 86.8%, 93.1%, and 90.0%, respectively. During follow‐up, 185/1302 patients (14.2%) developed tumor progression: 115 (8.8%) and 159 (12.2%) developed local regional recurrence and distant metastases, respectively. By last follow‐up, 153 patients had died; the majority (87.5%) of these deaths were attributed to NPC, and 19 (12.5%) had died of other causes.

Prognostic value of pretreatment anemia and CNN {#cam41233-sec-0011}
-----------------------------------------------

Patients without pretreatment anemia had significantly better 5‐year DMFS and DFS than patients with pretreatment anemia (88.0% vs.70.1%, *P *\<* *0.001; 78.6% vs. 63.1%, *P *=* *0.002), though 5‐year OS and 5‐year LRRFS were not significantly different between these groups (86.4% vs. 80.3%, *P *=* *0.116; 90.2% vs. 87.7%, *P *=* *0.319; Fig. [1](#cam41233-fig-0001){ref-type="fig"}). In multivariate analysis, after adjusting for various prognostic factors, pretreatment anemia was demonstrated to be an independent prognostic factor for DMFS (HR = 1.73, 95% CI: 1.01--2.70; *P *=* *0.048), but not OS, DFS or LRRFS. In addition, T category (HR = 1.96, 95% CI: 1.06--3.64; *P *=* *0.033) and N category (HR = 2.23, 95% CI: = 1.57--3.17; *P *\<* *0.001) were independent prognostic factor for DMFS. More information about the multivariate analyses is given in Table [2](#cam41233-tbl-0002){ref-type="table-wrap"} **.**

![Kaplan--Meier curves of overall (A), disease‐free (B), distant metastasis‐free (C), and locoregional relapse‐free (D) survival outcomes for the 1302 patients with NPC stratified by anemia.](CAM4-6-2822-g001){#cam41233-fig-0001}

###### 

Prognostic value of anemia for OS, DFS, DMFS, and LRRFS in the 1302 patients with NPC

  Endpoint        Variable            HR (95% CI)         *P*‐value[a](#cam41233-note-0006){ref-type="fn"}
  --------------- ------------------- ------------------- --------------------------------------------------
  OS              Anemia              NS                  
  WHO pathology   0.33 (0.20--0.55)   \<0.001             
  T category      3.78 (1.66--8.59)   0.002               
  N category      1.80 (1.25--2.60)   0.002               
  Age             1.97 (1.36--2.85)   \<0.001             
  Gender          NS                                      
  Chemotherapy    NS                                      
  DFS             Anemia              NS                  
  WHO pathology   0.47 (0.30--0.75)   0.001               
  T category      2.16 (1.35--3.50)   0.001               
  N category      1.55 (1.72--2.05)   0.002               
  Age             1.46 (1.12--1.90)   0.005               
  Gender          NS                                      
  Chemotherapy    NS                                      
  DMFS            Anemia              1.73 (1.01--2.70)   0.048
  WHO pathology   NS                                      
  T category      1.96 (1.06--3.64)   0.033               
  N category      2.23 (1.57--3.17)   \<0.001             
  Age             NS                                      
  Gender          NS                                      
  Chemotherapy    NS                                      
  LRRFS           Anemia              NS                  
  WHO pathology   0.33 (0.18--0.59)   \<0.001             
  T category      2.25 (1.14--4.46)   0.020               
  N category      NS                                      
  Age             NS                                      
  Gender          NS                                      
  Chemotherapy    NS                                      

NPC, nasopharyngeal carcinoma; HR, hazard ratio; CI, confidence interval; OS, overall survival; LRRFS, locoregional relapse‐free survival; DMFS, distant metastasis‐free survival; DFS, disease free survival; NS, not significant.

The following parameters were included in the Cox proportional hazards model multivariate analysis: WHO pathology (Type I‐II vs. Type III), gender (male vs. female), age (\>45 vs. ≤45 years), chemotherapy (yes vs. no), T category (T1--2 vs. T3--4), and N category (N1 vs. N2--3).
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Patients with CNN had significantly poorer 5‐year OS (82.6% vs. 87.8%, *P *=* *0.004), DFS (69.9% vs. 81.6%, *P *\<* *0.001), LRRFS (86% vs. 92.1%, *P *\<* *0.001) and DMFS (81.6% vs. 89.5%, *P *\<* *0.001) than patients without CNN (Fig. [2](#cam41233-fig-0002){ref-type="fig"}). Multivariate analyses demonstrated CNN was an independent prognostic factor for OS (HR = 1.50, 95% CI: 1.04--2.15; *P *=* *0.030), DFS (HR = 1.81, 95% CI: 1.31--3.36; *P *\<* *0.001), DMFS (HR = 1.70, 95% CI: 1.20--2.41; *P *=* *0.003) and LRRFS (HR = 2.20, 95% CI: 1.50--3.21; *P *\<* *0.001). In addition, WHO pathology, T category, N category and age were significant prognostic factor for OS and DFS; T category and N category were independent prognostic factors for DMFS; WHO pathogory and T category were independent prognostic factors for LRRFS. More information about the multivariate analyses is given in Table [3](#cam41233-tbl-0003){ref-type="table-wrap"}.

![Kaplan--Meier curves of overall (A), disease‐free (B), distant metastasis‐free (C), and locoregional relapse‐free (D) survival outcomes for the 1302 patients with NPC stratified by cervical node necrosis (CNN).](CAM4-6-2822-g002){#cam41233-fig-0002}

###### 

Prognostic value of cervical node necrosis (CNN) for OS, DFS, DMFS and LRRFS in the 1302 patients with NPC

  Endpoint       Variable            HR (95% CI)         *P‐*value[a](#cam41233-note-0008){ref-type="fn"}
  -------------- ------------------- ------------------- --------------------------------------------------
  OS             WHO pathology       0.33 (0.20--0.59)   \<0.001
  CNN            1.50 (1.04--2.15)   0.030               
  T category     3.69 (1.62--8.38)   0.002               
  N category     1.67 (1.14--2.43)   0.008               
  Age            1.47 (1.13--1.91)   \<0.001             
  Gender         NS                                      
  Chemotherapy   NS                                      
  DFS            WHO pathology       0.48 (0.31--0.76)   0.002
  CNN            1.81 (1.31--3.36)   \<0.001             
  T category     2.10 (1.31--3.36)   0.002               
  N category     1.42 (1.07--1.89)   0.015               
  Age            1.47 (1.13--1.91)   0.004               
  Gender         NS                                      
  Chemotherapy   NS                                      
  DMFS           WHO pathology       NS                  
                 CNN                 1.70 (1.20--2.41)   0.003
                 T category          1.92 (1.03--3.57)   0.039
                 N category          2.11 (1.48--3.00)   \<0.001
                 Age                 NS                  
                 Gender              NS                  
                 Chemotherapy        NS                  
  LRRFS          WHO pathology       0.33 (0.18--0.58)   \<0.001
                 CNN                 2.20 (1.50--3.21)   \<0.001
                 T category          2.09 (1.06--4.14)   0.035
                 N category          NS                  
                 Age                 NS                  
                 Gender              NS                  
                 Chemotherapy        NS                  

NPC, nasopharyngeal carcinoma; HR, hazard ratio; CI, confidence interval; OS, overall survival; LRRFS, locoregional relapse‐free survival; DMFS, distant metastasis‐free survival; DFS, disease free survival; NS, not significant.

The following parameters were included in the Cox proportional hazards model multivariate analysis: WHO pathology (Type I‐II vs. Type III), gender (male vs. female), age (\>45 vs. ≤45 years), chemotherapy (yes vs. no), T category (T1--2 vs. T3--4), and N category (N1 vs. N2--3).
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Combined prognostic value of pretreatment anemia and CNN {#cam41233-sec-0012}
--------------------------------------------------------

We classified the entire cohort into four groups using the two prognostic factors pretreatment anemia and CNN, as described above. Significant differences in OS, PFS, LRRFS, and DMFS were observed between the non‐anemia and non‐CNN group, anemia group, CNN group, and anemia and CNN groups: 5‐year OS was 88.9%, 70.1%, 84.0%, and 67.9% (*P *\<* *0.001); 5‐year DFS was 82.2%, 66.6%, 72.8%, and 39.9% (*P *\<* *0.001); 5‐year DMFS was 89.8%, 79.5%, 84.6%, and 50.6% (*P *\<* *0.001), and 5‐year LRRFS was 92.3%, 85.5%, 87.2%, and 71.8% (*P *\<* *0.001), respectively. Kaplan--Meier survival curves for the four groups are shown in Figure [3](#cam41233-fig-0003){ref-type="fig"}.

![Kaplan--Meier curves of overall (A), disease‐free (B), distant metastasis‐free (C), and locoregional relapse‐free (D) survival outcomes for the 1302 patients with NPC stratified by anemia combined with cervical node necrosis (CNN).](CAM4-6-2822-g003){#cam41233-fig-0003}

The anemia and CNN group had the poorest survival outcomes, and the non‐anemia and non‐CNN group had the best survival outcomes. The differences in survival between the four groups are presented in Figure [3](#cam41233-fig-0003){ref-type="fig"}. Compared with the non‐anemia and non‐CNN group, the anemia group, CNN group, anemia and CNN group experienced poorer OS, DMFS, LRRFS, and DFS. In addition, the anemia and CNN group had poorer OS, DMFS, LRRFS and DFS than the CNN group; and the anemia and CNN group had poorer DMFS and DFS than the anemia group. There was no significant difference in any end‐point between the anemia group and CNN group.

Multivariate analysis demonstrated that the combined classification was an independent prognostic factor for OS (*P *=* *0.034), DMFS (*P *=* *0.001), LRRFS (*P *\<* *0.001), and DFS (*P *=* *0.001). WHO pathology, T category, N category, and age were significant prognostic factor for OS and DFS; N caterogy was an independent prognostic factor for OS; and WHO pathogory was an independent prognostic factor for LRRFS. In addition, the anemia and CNN group had much higher HRs for OS, DMFS, LRRFS, and DFS than the other three groups, whereas the non‐anemia and non‐CNN group had the lowest HRs for all endpoints (Table [4](#cam41233-tbl-0004){ref-type="table-wrap"}).

###### 

Combined prognostic value of anemia and cervical node necrosis (CNN) for OS, DFS, DMFS and LRRFS in the 1302 patients with NPC

  Endpoint                   Variable                                        HR (95% CI)         *P*‐value[a](#cam41233-note-0010){ref-type="fn"}
  -------------------------- ------------------------ ---------------------- ------------------- --------------------------------------------------
  OS                         WHO pathology                                   0.34 (0.20--0.58)   \<0.001
  CNN and anemia                                                             0.034               
                             Non‐anemia and non‐CNN   Reference                                  
                             Anemia                   2.17 (1.03--4.57)      0.041               
                             CNN                      1.48 (1.00--2.17)      0.048               
                             Anemia and CNN           2.42 (1.02--5.75)      0.046               
  T category                                          3.29 (1.44--7.53)      0.003               
  N category                                          1.55 (1.05--2.27)      0.022               
  Age                                                 2.01 (1.38--2.91)      \<0.001             
  Gender                                              NS                                         
  Chemotherapy                                        NS                                         
  DFS                        WHO pathology                                   0.49 (0.32--0.78)   0.003
  CNN combined with anemia                                                   \<0.001             
                             Non‐anemia and non‐CNN   Reference                                  
                             Anemia                   1.64 (0.88--3.06)      0.120               
                             CNN                      1.64 (1.24--2.18)      0.001               
                             Anemia and CNN           4.09 (2.230--7.29)     0.000               
  T category                                          1.98 (1.23--3.19)      0.005               
  N category                                          1.34 (1.06--1.79)      0.046               
  Age                                                 1.47 (1.11--1.92)      0.004               
  Gender                                              NS                                         
  Chemotherapy                                        NS                                         
  DMFS                       WHO pathology                                   NS                  
  CNN combined with anemia                                                   0.001               
                             Non‐anemia and non‐CNN   Reference                                  
                             Anemia                   1.29 (0.54--3.21)      0.591               
                             CNN                      1.43 (0.99--2.08)      0.060               
  T category                                          NS                                         
  N category                                          1.97 (1.37--2.82)      \<0.001             
                             Anemia and CNN           4.29 (2.14--8.58)      \<0.001             
  Age                                                 NS                                         
  Gender                                              NS                                         
  Chemotherapy                                        NS                                         
  LRRFS                      WHO pathology                                   0.34 (0.19--0.61)   \<0.001
  CNN combined with anemia                                                   \<0.001             
                             Non‐anemia and non‐CNN   Reference                                  
                             Anemia                   2.19 (0.93--5.12)      0.071               
                             CNN                      2.08 (1.39--3.13)      \<0.001             
                             Anemia and CNN           5.2878 (2.37--11.74)   \<0.001             
  T category                                                                                     
  N category                                                                                     
  Age                                                 NS                                         
  Gender                                              NS                                         
  Chemotherapy                                        NS                                         

NPC, nasopharyngeal carcinoma; HR, hazard ratio; CI, confidence interval; OS, overall survival; LRRFS, locoregional relapse‐free survival; DMFS, distant metastasis‐free survival; DFS, disease‐free survival; NS, not significant.

The following parameters were included in the Cox proportional hazards model multivariate analysis: WHO pathology (Type I‐II vs. Type III), gender (male vs. female), age (\>45 vs. ≤45 years), chemotherapy (yes vs. no), T category (T1--2 vs. T3--4), and N category (N1 vs. N2--3).
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Discussion {#cam41233-sec-0013}
==========

Radioresistance and chemoresistance are the major factors associated with poor locoregional control and distant failure in malignant tumors [8](#cam41233-bib-0008){ref-type="ref"}. Tumor hypoxia plays a major role in radioresistance and chemoresistance [9](#cam41233-bib-0009){ref-type="ref"}, [10](#cam41233-bib-0010){ref-type="ref"}. Recent evidence indicates both anemia and CNN are associated with tumor hypoxia, which negatively impact treatment efficacy [11](#cam41233-bib-0011){ref-type="ref"}, [12](#cam41233-bib-0012){ref-type="ref"}, [13](#cam41233-bib-0013){ref-type="ref"}, [14](#cam41233-bib-0014){ref-type="ref"}, [15](#cam41233-bib-0015){ref-type="ref"}, [16](#cam41233-bib-0016){ref-type="ref"}, [17](#cam41233-bib-0017){ref-type="ref"}. Therefore, a large population‐based study was performed to determine the combined prognostic value of anemia and CNN in current study. Based on this work, we propose a new prognostic model that enables accurate stratification of individual patients with NPC receiving IMRT ± chemotherapy into four risk groups.

This study revealed pretreatment anemia was a prognostic factor for poorer DMFS, and pretreatment CNN was a prognostic factor for poorer OS, DFS, DMFS, and LRRFS. Therefore, we sought to establish a prognostic model. The non‐anemia and non‐CNN group had better survival outcomes than the anemia group, CNN group, anemia and CNN group, and the anemia and CNN group experienced the poorest survival outcomes. The combined classification was an independent prognostic factor for OS, LRRFS, DMFS, and DFS. The anemia and CNN group had much higher HRs for all endpoints than the other three groups, indicating combined assessment of CNN and anemia improves risk stratification and prognostication and suggesting more intensive treatment modality may be more suitable for patients with pretreatment anemia and CNN.

The prognostic significance of low pretreatment anemia has previously been investigated in various cancers; low Hb is associated with poorer outcomes in many types of human cancer, particularly in HN cancers and gynecological tumors [26](#cam41233-bib-0026){ref-type="ref"}, [27](#cam41233-bib-0027){ref-type="ref"}, [28](#cam41233-bib-0028){ref-type="ref"}. A positive relationship between survival outcomes and Hb levels has been demonstrated in patients with NPC receiving RT ± chemotherapy: low pretreatment Hb was related to increased risk of death or metastasis [11](#cam41233-bib-0011){ref-type="ref"}, [12](#cam41233-bib-0012){ref-type="ref"}, [13](#cam41233-bib-0013){ref-type="ref"}, [14](#cam41233-bib-0014){ref-type="ref"}, [15](#cam41233-bib-0015){ref-type="ref"}.

Moreover, CNN has also been demonstrated to have prognostic value in HN cancer after RT and/or chemotherapy [29](#cam41233-bib-0029){ref-type="ref"}, [30](#cam41233-bib-0030){ref-type="ref"}, [31](#cam41233-bib-0031){ref-type="ref"}: the presence of hypodense lymph nodes, which indicate CNN [17](#cam41233-bib-0017){ref-type="ref"}, was associated with regional treatment failure. Lan et al. [14](#cam41233-bib-0014){ref-type="ref"} were the first to report CNN was a negative prognostic factor for OS, DMFS, RRFS, and DFS in patients with NPC treated using IMRT, three‐dimensional radiotherapy (3D‐RT) or 2D‐RT. Moreover, in a recent study by Zhang et al., CNN was demonstrated to be an independent, adverse prognostic factor for OS, DFS, LRRFS, and DMFS in patients with NPC treated with IMRT [17](#cam41233-bib-0017){ref-type="ref"}.

The major purpose of this research was to combine the prognostic value of anemia and CNN to improve risk stratification and prognostication in NPC. We found the combination of anemia and CNN improved prognostic ability. However, the precise mechanisms underlying the cumulative adverse effect of anemia and CNN remain unclear. As both anemia and CNN are associated with hypoxia, we speculate the presence of both may indicate more severe tumor hypoxia compared to one factor alone. As there is a potential relationship between hypoxia and radioresistance and chemoresistance and the anemia and CNN group had the poorest prognosis compared to the other three groups, we suggest more aggressive IMRT ± chemotherapy protocols should be designed for high‐risk patients with anemia and CNN.

The principal limitation of this study was the fact treatment heterogeneity was inevitable as this was a retrospective analysis of patients with NPC from a single institution. Thus, a large, multicenter prospective study is required to further confirm the findings of current research.

Conclusion {#cam41233-sec-0014}
==========

Classification combining anemia and CNN is an independent prognostic factor for OS, DFS, DMFS, and LRRFS in patients with NPC treated with IMRT ± chemotherapy. Combined assessment of anemia and CNN improves risk stratification and prognostication: patients in the non‐anemia and non‐CNN group had the best survival outcomes; and the anemia and CNN group experienced the poorest survival outcomes. This data may aid the design of individualized treatment plans to improve the treatment outcomes of patients with NPC receiving IMRT ± chemotherapy.
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